Food Safety Officials from the Food & Drug Administration (FDA), Maharashtra, visited FDC Limited depots in Chhatrapati Sambhaji Nagar and Nagpur on June 3, 2026, seizing certain stock of the company's product 'Enerzal' and collecting samples for examination regarding alleged misbranding. The company stated that the final examination order is pending and it will take appropriate legal recourse, while business operations continue as usual.

Regulatory Action

The FDA's action involves the seizure of stock and the collection of samples for examination. According to the disclosure, the inspection relates to the alleged misbranding of the product. The company received the communication regarding this action on June 3, 2026. As of the filing date, the final examination order is yet to be received.

Company Response

FDC Limited stated that there is no material financial impact on the company or its operations as of the current date. The company has indicated its intent to pursue appropriate legal recourse in response to the regulatory action. Stakeholders are advised to await further official communication regarding the outcome of the examination.

FDC Limited reported a 5.5% year-on-year increase in consolidated net profit to ₹281 crore for the financial year ended March 31, 2026. The board approved the audited standalone and consolidated financial results at a meeting held on May 27, 2026. M/s. BSR & Co. LLP, the Statutory Auditors, issued an unmodified opinion on the results. For the quarter ended March 31, 2026, consolidated net profit surged 167.4% to ₹103 crore, driven by robust revenue growth and enhanced operational efficiencies.

Q4 and Annual Performance

Q4 FY26 revenue from operations stood at ₹585 crore, a robust increase of 18.9% compared to ₹492 crore in the corresponding quarter of the previous year. For the full year, revenue from operations increased to ₹2,171 crore from ₹2,108 crore in FY25. EBITDA for Q4 FY26 stood at ₹106 crore, with margins expanding to 18.2% from 11.0% in the prior year. FY26 EBITDA margin improved to 15.9% from 15.4% year-on-year, driven by higher gross margins.

The following table summarizes FDC's key consolidated financial metrics for Q4 and FY26:

Operational Highlights

All three business segments achieved healthy growth during the quarter. Domestic Formulations business grew by 8.5%, Export Formulations business grew by 99.3%, and the API business grew by 38.6%. The US business overcame earlier challenges to deliver strong performance, with revenue from supplies standing at ₹71 crore, reflecting a year-on-year growth of 165.1%. Overall US business revenue grew 46.9% year-on-year, supported by improved profit share from US partners.

Business Segment Performance

Domestic Formulations revenue stood at ₹452 crore in Q4 FY26. For FY26, sales were ₹1,781 crore, displaying a muted growth of 0.1% compared to the corresponding period last year due to subdued performance in top brands like Zifi, Electral, and Enerzal. Export Formulations sales stood at ₹89 crore in Q4 FY26. During the quarter, the company received U.S. FDA approval for Fluconazole Tablets USP 50mg, 100mg, 150mg, and 200mg. API business registered sales of ₹42 crore in Q4 FY26, up by 38.6% year-on-year, and recorded sales of ₹121 crore for FY26.